# Cost-Effectiveness of Preventing HIV Complications

> **NIH NIH R01** · MASSACHUSETTS GENERAL HOSPITAL · 2021 · $806,891

## Abstract

Project Summary
Even with effective, safe, and simple antiretroviral therapy (ART) regimens and effective pre-exposure
prophylaxis (PrEP) for HIV treatment and prevention, the US continues to have around 40,000 new HIV
diagnoses each year. Among people with HIV, many experience barriers to accessing needed services and
experience poor clinical outcomes, often exacerbated by geographic, racial, and economic disparities. Along
with the high costs of care, these disparities contribute to ongoing incidence and low rates of diagnosis,
engagement in HIV care, and virologic suppression. Earlier this year, DHHS announced a new plan to End the
HIV Epidemic (EHE) in the US, with a target to decrease new infections by 90% within ten years, prompting
new efforts around how to best mobilize and utilize resources towards this goal. This competing continuation
proposes to expand upon the Cost-effectiveness of Preventing AIDS Complications (CEPAC) Model, a
computer microsimulation model of HIV disease prevention and treatment, to identify the most effective and
cost-effective combination of strategies to end the HIV epidemic in the US. In addition to evaluating emerging
biomedical therapies for HIV and interventions along the continuum of HIV care, the research team will work
with the public health departments of Los Angeles County, California, and Fulton County, Georgia, to allow for
assessment of specific interventions tailored to the epidemic in different jurisdictions. This proposal has two
specific aims:
Aim 1. To investigate the clinical impact, cost, and cost-effectiveness of interventions throughout the
HIV care continuum, including PrEP for prevention, engagement in care, and new treatment regimens.
Aim 2. To evaluate the clinical impact, cost, and cost-effectiveness of comprehensive efforts to reach
the End the HIV Epidemic targets in the US, and to develop optimization models to assess the most
efficient approach to reaching these goals.
Aligned with the research priorities of the NIH Office of AIDS Research to reduce the incidence of HIV and
evaluate next-generation HIV therapies, the CEPAC team will leverage the strengths of mathematical
simulation modeling along with new optimization methods. This effort will highlight the value of new HIV
therapies and continuum of care interventions and provide evidence to inform decisionmakers about the most
effective strategies to reach the End the HIV Epidemic targets.

## Key facts

- **NIH application ID:** 10172826
- **Project number:** 5R01AI042006-25
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** Kenneth Alan Freedberg
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $806,891
- **Award type:** 5
- **Project period:** 1998-04-01 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10172826

## Citation

> US National Institutes of Health, RePORTER application 10172826, Cost-Effectiveness of Preventing HIV Complications (5R01AI042006-25). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10172826. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*